Skip to main content
OpenTrials
Completed

NCT Number: NCT04320498

Short Term Results of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure

Autologous PRP currently has many uses in surgical and medical therapy. Compared with other regenerative therapies, PRP is easy-to-prepare, low-cost, and does not require complex equipment. The use of autologous PRP avoids immunological side effects. Data is lacking on the use of PRP in the treatment of anal fissure. This study evaluated PRP as an alternative medical treatment for chronic anal fissures.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Karatay Medicana Üniversitesi

Konya, Turkey (Türkiye)

About this study

. Chronic anal fissures are mucosal ulcers in the anal canal distal to the dentate line and most often present with severe pain and bleeding during defecation. The symptoms of chronic anal fissures persist for more than 8 weeks and do not respond well to medical treatment. This randomized controlled trial investigated the effects of PRP on the healing of chronic anal fissures, which can be considered as nonhealing ulcers. High anal sphincter pressure can cause chronic anal fissures by producing mucosal ischemia in the posterior anal canal that delays wound healing, ultimately resulting in a chronic nonhealing ulcer. Increased anal sphincter pressure induces constipation and spasms in the arterioles that form the mucosal blood supply.9 Botulinum toxin, calcium channel blockers, nitrates, or surgery promote healing by reducing anal sphincter pressure, and increasing blood flow.

Autologous PRP has been shown to speed recovery and improve pain and quality of life scores of patients treated for chronic wounds.PRP reduced complaints and accelerated epithelialization and healing in patients with chronic anal fissures. PRP, which can be obtained easily and did not have any harmful patient effects may be an alternative to surgery in patients with chronic anal fissures. The duration of symptoms should be considered during the evaluation of treatment options.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • between 18 and 65 years of age with painful defecation of at least 2 months duration and diagnosed with anal fissure between January and October 2019 were included.
  • The diagnosis of chronic anal fissure required :
  • the presence of internal sphincter muscle fibers in the base of the fissure
  • hypertrophic anal papillae on digital rectal examination

Exclusion criteria

  • Patients with physical examination findings that did not meet the definition of chronic anal fissure
  • with painful defecation for less than 2 months,
  • atypical fissure location or multiple anal fissures away from the midline
  • inflammatory bowel disease
  • cancer
  • history of trauma
  • tuberculosis
  • immune suppression
  • sexually transmitted disease
  • a disease possibly associated with a fissure
  • a history of anal surgery
  • previous treatment for anal fissure
  • current pregnancy .

Treatment and study plan

PRP injection

Biological

PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.

Other names: Platelet rich plasma injection

Anrecta

Drug

self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day

Other names: rectoderm

sitz bath

Behavioral

participants were told to take a hot water sitz bath once a day

nutrition regulation

Dietary Supplement

The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily

Primary outcomes

  1. effects of PRP treatment on epithelization .

    Time frame: 10 days , 1 month and 2 months

    In a clean surgical wound, the epithelial cells migrate downward to meet deep in the dermis. Migration ceases when the layer is rejuvenated. Following surgery, this process is normally complete within 48 hours. However, the process of epithelialization is difficult in wounds that are not primarily closed or need to heal by secondary intention. In these wounds, the physical distance of epithelial migration is changed across the length, width, and depth of the wound. In chronic anal fissures, wound epithelization can be evaluated by inspection. Approximately 80 percent of the original strength of the tissue is obtained within six weeks. So we planned to make this assessment on the 10th Day, 1st Month, and 2nd Month for the reason I explained above. We considered the complete epithelization of the fissure as a complete healing. We evaluated patients with epithelialization in the midline but incomplete as partial epithelization.

  2. effect of PRP treatment on VAS scores

    Time frame: 10 days , 1 month and 2 months

    Distribution of the effect of PRP treatment on VAS scores. The VAS is a simple scale with a length of 100 mm on which patients were asked to rate their pain from 0 (absence of pain) to 100 (worst pain imaginable).

    In connection with wound healing, we expect the pain to change. The process of epithelialization is difficult in wounds that are not primarily closed or need to heal by secondary intention. In these wounds, the physical distance of epithelial migration is changed across the length, width, and depth of the wound. So we planned to make this assessment on the 10th Day to evaluate early pain control. we planned In the first month, to evaluate the middle period pain control and in the second month to evaluate the late period pain control.

Secondary outcomes

  1. effect of PRP treatment on symptoms

    Time frame: 10 days , 1 month and 2 months

    Distribution of the effect of PRP treatment on symptoms Presenting symptoms including constipation, pruritus, presence of skin tags, and bleeding was recorded on enrolment. In connection with wound healing, we expect symptoms such as constipation, pruritus, and bleeding to change. we assessed the decline in constipation, pruritus, and bleeding from the start of treatment. we record the symptoms of the patients on the 10th Day, the first month, and the second month. Thus, we compared the response to treatment in the early, middle, and late periods.

  2. Comparison of the effect of treatments on pain according to the onset of symptoms of patients

    Time frame: 10 days , 1 month and 2 months

    The duration of the associated complaints and symptoms distinguishes acute from chronic anal fissures, which are evaluated and treated as conditions with different etiologies and physiology. Acute anal fissures have symptoms of < 8 weeks duration. Chronic anal fissure symptoms have persisted for 8 weeks or longer. The effectiveness of medical treatment changes with time after the appearance of the first anal fissure symptoms and ultimately becomes less effective than surgery. we evaluated the effect of treatments on symptoms according to the onset of symptoms of patients. we evaluated VAS scores on day 10, months 1, and 2 in patients with fissures for less than 12 months than in those with fissures of longer duration.

Sponsors and collaborators

Lead sponsor

KTO Karatay University

Other

Collaborators

  • Istanbul Medipol University Hospital

Registry information

Official study title

Effects of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure

Important dates

Study start
2019
Primary completion
2019
Study completion
2021
First posted
Mar 25, 2020
Registry last updated
Apr 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.